{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:57:25Z","timestamp":1791874645722,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007388"],"award-info":[{"award-number":["T32GM007388"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007388"],"award-info":[{"award-number":["T32GM007388"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35 GM119850"],"award-info":[{"award-number":["R35 GM119850"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24GM137782"],"award-info":[{"award-number":["R24GM137782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI132212"],"award-info":[{"award-number":["R01 AI132212"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI132212"],"award-info":[{"award-number":["R01 AI132212"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168048"],"award-info":[{"award-number":["R01 AI168048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI132212"],"award-info":[{"award-number":["R01 AI132212"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI132212"],"award-info":[{"award-number":["R01 AI132212"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF20SA0066621"],"award-info":[{"award-number":["NNF20SA0066621"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF20SA0066621"],"award-info":[{"award-number":["NNF20SA0066621"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01161-6","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:07:15Z","timestamp":1749625635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity"],"prefix":"10.1038","volume":"10","author":[{"given":"Liudmila","family":"Kulakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiki H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin W. T.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Schwoerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Schoffelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija H.","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinlin L.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Archer-Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Azadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn G.","family":"Voldborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy A.","family":"Mariuzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K.","family":"Andrianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ploss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fuerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"1161_CR1","unstructured":"WHO. Global Hepatitis Report 2024 (World Health Organization, 2024)."},{"key":"1161_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cid\/ciw111","volume":"62","author":"KN Ly","year":"2016","unstructured":"Ly, K. N., Hughes, E. M., Jiles, R. B. & Holmberg, S. D. Rising mortality associated with hepatitis C Virus in the United States, 2003-2013. Clin. Infect. Dis. 62, 1287\u20131288 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"1161_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang, T. J. & Ghany, M. G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 368, 1907\u20131917 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1161_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm.3248","volume":"19","author":"TK Scheel","year":"2013","unstructured":"Scheel, T. K. & Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19, 837\u2013849 (2013).","journal-title":"Nat. Med."},{"key":"1161_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1126\/science.aad1302","volume":"349","author":"AL Cox","year":"2015","unstructured":"Cox, A. L. MEDICINE. Global control of hepatitis C virus. Science 349, 790\u2013791 (2015).","journal-title":"Science"},{"key":"1161_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nature04079","volume":"436","author":"DG Bowen","year":"2005","unstructured":"Bowen, D. G. & Walker, C. M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436, 946\u2013952 (2005).","journal-title":"Nature"},{"key":"1161_CR7","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","volume":"359","author":"SH Mehta","year":"2002","unstructured":"Mehta, S. H. et al. Protection against persistence of hepatitis C. Lancet 359, 1478\u20131483 (2002).","journal-title":"Lancet"},{"key":"1161_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","volume":"138","author":"WO Osburn","year":"2010","unstructured":"Osburn, W. O. et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138, 315\u2013324 (2010).","journal-title":"Gastroenterology"},{"key":"1161_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1086\/605947","volume":"200","author":"K Page","year":"2009","unstructured":"Page, K. et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J. Infect. Dis. 200, 1216\u20131226 (2009).","journal-title":"J. Infect. Dis."},{"key":"1161_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0034-1371081","volume":"34","author":"JR Honegger","year":"2014","unstructured":"Honegger, J. R., Zhou, Y. & Walker, C. M. Will there be a vaccine to prevent HCV infection?. Semin. Liver Dis. 34, 79\u201388 (2014).","journal-title":"Semin. Liver Dis."},{"key":"1161_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.79","volume":"2","author":"L Man John Law","year":"2013","unstructured":"Man John Law, L., Landi, A., Magee, W. C., Lorne Tyrrell, D. & Houghton, M. Progress towards a hepatitis C virus vaccine. Emerg. Microbes Infect. 2, e79 (2013).","journal-title":"Emerg. Microbes Infect."},{"key":"1161_CR12","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.3390\/v7072809","volume":"7","author":"AW Tarr","year":"2015","unstructured":"Tarr, A. W. et al. Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design. Viruses 7, 3995\u20134046 (2015).","journal-title":"Viruses"},{"key":"1161_CR13","doi-asserted-by":"publisher","first-page":"11078","DOI":"10.1128\/JVI.00800-09","volume":"83","author":"J Whidby","year":"2009","unstructured":"Whidby, J. et al. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J. Virol. 83, 11078\u201311089 (2009).","journal-title":"J. Virol."},{"key":"1161_CR14","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.1074\/jbc.RA120.013015","volume":"295","author":"RJ Center","year":"2020","unstructured":"Center, R. J. et al. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. J. Biol. Chem. 295, 7179\u20137192 (2020).","journal-title":"J. Biol. Chem."},{"key":"1161_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2015149118","volume":"118","author":"JD Guest","year":"2021","unstructured":"Guest, J. D. et al. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Proc. Natl. Acad. Sci. USA 118, e2015149118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR16","doi-asserted-by":"publisher","first-page":"e02141","DOI":"10.1128\/JVI.02141-17","volume":"92","author":"JLM Law","year":"2018","unstructured":"Law, J. L. M. et al. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. J. Virol. 92, e02141\u201302117 (2018).","journal-title":"J. Virol."},{"key":"1161_CR17","doi-asserted-by":"publisher","first-page":"10486","DOI":"10.1128\/JVI.01462-16","volume":"90","author":"D Li","year":"2016","unstructured":"Li, D. et al. Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice. J. Virol. 90, 10486\u201310498 (2016).","journal-title":"J. Virol."},{"key":"1161_CR18","doi-asserted-by":"publisher","first-page":"e00704","DOI":"10.1128\/JVI.00704-20","volume":"94","author":"BG Pierce","year":"2020","unstructured":"Pierce, B. G. et al. Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization. J. Virol. 94, e00704\u2013e00720 (2020).","journal-title":"J. Virol."},{"key":"1161_CR19","doi-asserted-by":"publisher","first-page":"e01403","DOI":"10.1128\/JVI.01403-18","volume":"93","author":"RA Urbanowicz","year":"2019","unstructured":"Urbanowicz, R. A. et al. Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells. J. Virol. 93, e01403\u2013e01418 (2019).","journal-title":"J. Virol."},{"key":"1161_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hep.28989","volume":"65","author":"PT Vietheer","year":"2017","unstructured":"Vietheer, P. T. et al. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology 65, 1117\u20131131 (2017).","journal-title":"Hepatology"},{"key":"1161_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jhep.2024.06.029","volume":"81","author":"J Kundu","year":"2024","unstructured":"Kundu, J. et al. Recombinant H77C gpE1\/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone. J. Hepatol. 81, 941\u2013948 (2024).","journal-title":"J. Hepatol."},{"key":"1161_CR22","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","volume":"91","author":"QL Choo","year":"1994","unstructured":"Choo, Q. L. et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 91, 1294\u20131298 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","volume":"239","author":"M Houghton","year":"2011","unstructured":"Houghton, M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 239, 99\u2013108 (2011).","journal-title":"Immunol. Rev."},{"key":"1161_CR24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/infdis\/jir511","volume":"204","author":"JC Meunier","year":"2011","unstructured":"Meunier, J. C. et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J. Infect. Dis. 204, 1186\u20131190 (2011).","journal-title":"J. Infect. Dis."},{"key":"1161_CR25","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1099\/0022-1317-81-10-2451","volume":"81","author":"T Allander","year":"2000","unstructured":"Allander, T. et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J. Gen. Virol. 81, 2451\u20132459 (2000).","journal-title":"J. Gen. Virol."},{"key":"1161_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","volume":"598","author":"A Kumar","year":"2021","unstructured":"Kumar, A. et al. Structural insights into hepatitis C virus receptor binding and entry. Nature 598, 521\u2013525 (2021).","journal-title":"Nature"},{"key":"1161_CR27","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1128\/JVI.00271-06","volume":"80","author":"AM Owsianka","year":"2006","unstructured":"Owsianka, A. M. et al. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80, 8695\u20138704 (2006).","journal-title":"J. Virol."},{"key":"1161_CR28","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1172\/JCI130720","volume":"129","author":"VJ Kinchen","year":"2019","unstructured":"Kinchen, V. J. et al. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. J. Clin. Invest. 129, 4786\u20134796 (2019).","journal-title":"J. Clin. Invest."},{"key":"1161_CR29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fimmu.2018.00910","volume":"9","author":"M Lavie","year":"2018","unstructured":"Lavie, M., Hanoulle, X. & Dubuisson, J. Glycan shielding and modulation of hepatitis C virus neutralizing antibodies. Front. Immunol. 9, 910 (2018).","journal-title":"Front. Immunol."},{"key":"1161_CR30","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1002\/1873-3468.13177","volume":"592","author":"I Bagdonaite","year":"2018","unstructured":"Bagdonaite, I., Vakhrushev, S. Y., Joshi, H. J. & Wandall, H. H. Viral glycoproteomes: technologies for characterization and outlook for vaccine design. FEBS Lett. 592, 3898\u20133920 (2018).","journal-title":"FEBS Lett."},{"key":"1161_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature13117","volume":"509","author":"AG Khan","year":"2014","unstructured":"Khan, A. G. et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509, 381\u2013384 (2014).","journal-title":"Nature"},{"key":"1161_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090\u20131094 (2013).","journal-title":"Science"},{"key":"1161_CR33","unstructured":"Lavie, M., Goffard, A. & Dubuisson, J. in (ed. Tan, S. L.) Hepatitis C Viruses: Genomes and Molecular Biology (Norfolk, 2006)."},{"key":"1161_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.32607\/20758251-2015-7-1-87-97","volume":"7","author":"OV Orlova","year":"2015","unstructured":"Orlova, O. V. et al. The role of HCV e2 protein glycosylation in functioning of virus envelope proteins in insect and Mammalian cells. Acta Nat. 7, 87\u201397 (2015).","journal-title":"Acta Nat."},{"key":"1161_CR35","doi-asserted-by":"publisher","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","volume":"79","author":"A Goffard","year":"2005","unstructured":"Goffard, A. et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79, 8400\u20138409 (2005).","journal-title":"J. Virol."},{"key":"1161_CR36","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3389\/fimmu.2018.01315","volume":"9","author":"N Tzarum","year":"2018","unstructured":"Tzarum, N., Wilson, I. A. & Law, M. The neutralizing face of hepatitis C virus E2 envelope glycoprotein. Front. Immunol. 9, 1315 (2018).","journal-title":"Front. Immunol."},{"key":"1161_CR37","doi-asserted-by":"publisher","first-page":"11905","DOI":"10.1128\/JVI.01548-10","volume":"84","author":"F Helle","year":"2010","unstructured":"Helle, F. et al. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 84, 11905\u201311915 (2010).","journal-title":"J. Virol."},{"key":"1161_CR38","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1128\/JVI.00459-07","volume":"81","author":"E Falkowska","year":"2007","unstructured":"Falkowska, E., Kajumo, F., Garcia, E., Reinus, J. & Dragic, T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81, 8072\u20138079 (2007).","journal-title":"J. Virol."},{"key":"1161_CR39","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1093\/bioinformatics\/bts541","volume":"28","author":"F Xin","year":"2012","unstructured":"Xin, F. & Radivojac, P. Post-translational modifications induce significant yet not extreme changes to protein structure. Bioinformatics 28, 2905\u20132913 (2012).","journal-title":"Bioinformatics"},{"key":"1161_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00018-002-8437-3","volume":"59","author":"E Lisowska","year":"2002","unstructured":"Lisowska, E. The role of glycosylation in protein antigenic properties. Cell Mol. Life Sci. 59, 445\u2013455 (2002).","journal-title":"Cell Mol. Life Sci."},{"key":"1161_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.celrep.2017.04.013","volume":"19","author":"T Zhou","year":"2017","unstructured":"Zhou, T. et al. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep. 19, 719\u2013732 (2017).","journal-title":"Cell Rep."},{"key":"1161_CR42","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nchembio.1403","volume":"9","author":"MA Wolfert","year":"2013","unstructured":"Wolfert, M. A. & Boons, G. J. Adaptive immune activation: glycosylation does matter. Nat. Chem. Biol. 9, 776\u2013784 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"1161_CR43","doi-asserted-by":"crossref","unstructured":"Huang, H. Y. et al. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. Sci. Transl. Med. 14, eabm0899 (2022).","DOI":"10.1126\/scitranslmed.abm0899"},{"key":"1161_CR44","doi-asserted-by":"publisher","first-page":"18137","DOI":"10.1073\/pnas.0909696106","volume":"106","author":"CC Wang","year":"2009","unstructured":"Wang, C. C. et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl. Acad. Sci. USA 106, 18137\u201318142 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37742-z","volume":"14","author":"YN Zhang","year":"2023","unstructured":"Zhang, Y. N. et al. Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates. Nat. Commun. 14, 1985 (2023).","journal-title":"Nat. Commun."},{"key":"1161_CR46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nbt.1932","volume":"29","author":"X Xu","year":"2011","unstructured":"Xu, X. et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol. 29, 735\u2013741 (2011).","journal-title":"Nat. Biotechnol."},{"key":"1161_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nbt.3280","volume":"33","author":"Z Yang","year":"2015","unstructured":"Yang, Z. et al. Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat. Biotechnol. 33, 842\u2013844 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1161_CR48","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nbt.2624","volume":"31","author":"NE Lewis","year":"2013","unstructured":"Lewis, N. E. et al. Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nat. Biotechnol. 31, 759\u2013765 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1161_CR49","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1021\/acs.jproteome.8b00935","volume":"18","author":"S Li","year":"2019","unstructured":"Li, S. et al. Proteogenomic annotation of Chinese hamsters reveals extensive novel translation events and endogenous retroviral elements. J. Proteome Res. 18, 2433\u20132445 (2019).","journal-title":"J. Proteome Res."},{"key":"1161_CR50","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/bit.26722","volume":"115","author":"O Rupp","year":"2018","unstructured":"Rupp, O. et al. A reference genome of the Chinese hamster based on a hybrid assembly strategy. Biotechnol. Bioeng. 115, 2087\u20132100 (2018).","journal-title":"Biotechnol. Bioeng."},{"key":"1161_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymben.2015.10.007","volume":"33","author":"PN Spahn","year":"2016","unstructured":"Spahn, P. N. et al. A Markov chain model for N-linked protein glycosylation\u2013towards a low-parameter tool for model-driven glycoengineering. Metab. Eng. 33, 52\u201366 (2016).","journal-title":"Metab. Eng."},{"key":"1161_CR52","doi-asserted-by":"publisher","first-page":"1600489","DOI":"10.1002\/biot.201600489","volume":"12","author":"PN Spahn","year":"2017","unstructured":"Spahn, P. N., Hansen, A. H., Kol, S., Voldborg, B. G. & Lewis, N. E. Predictive glycoengineering of biosimilars using a Markov chain glycosylation model. Biotechnol. J. 12, 1600489 (2017).","journal-title":"Biotechnol. J."},{"key":"1161_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.crbiot.2020.01.001","volume":"2","author":"C Liang","year":"2020","unstructured":"Liang, C. et al. A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering. Curr. Res. Biotechnol. 2, 22\u201336 (2020).","journal-title":"Curr. Res. Biotechnol."},{"key":"1161_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700686","volume":"14","author":"D Reinhart","year":"2019","unstructured":"Reinhart, D. et al. Bioprocessing of recombinant CHO-K1, CHO-DG44, and CHO-S: CHO expression hosts favor either mAb production or biomass synthesis. Biotechnol. J. 14, e1700686 (2019).","journal-title":"Biotechnol. J."},{"key":"1161_CR55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112008119","volume":"119","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. Proc. Natl. Acad. Sci. USA 119, e2112008119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm1698","volume":"14","author":"M Law","year":"2008","unstructured":"Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14, 25\u201327 (2008).","journal-title":"Nat. Med."},{"key":"1161_CR57","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/hep.28850","volume":"64","author":"ZY Keck","year":"2016","unstructured":"Keck, Z. Y. et al. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology 64, 1922\u20131933 (2016).","journal-title":"Hepatology"},{"key":"1161_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10719-015-9626-2","volume":"33","author":"F Clerc","year":"2016","unstructured":"Clerc, F. et al. Human plasma protein N-glycosylation. Glycoconj. J. 33, 309\u2013343 (2016).","journal-title":"Glycoconj. J."},{"key":"1161_CR59","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.xphs.2017.04.048","volume":"106","author":"AV Gandhi","year":"2017","unstructured":"Gandhi, A. V., Pothecary, M. R., Bain, D. L. & Carpenter, J. F. Some lessons learned from a comparison between sedimentation velocity analytical ultracentrifugation and size exclusion chromatography to characterize and quantify protein aggregates. J. Pharm. Sci. 106, 2178\u20132186 (2017).","journal-title":"J. Pharm. Sci."},{"key":"1161_CR60","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1021\/acsabm.0c00189","volume":"3","author":"AK Andrianov","year":"2020","unstructured":"Andrianov, A. K. et al. Supramolecular assembly of Toll-like receptor 7\/8 agonist into multimeric water-soluble constructs enables superior immune stimulation. ACS Appl Bio Mater. 3, 3187\u20133195 (2020).","journal-title":"ACS Appl Bio Mater."},{"key":"1161_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jconrel.2020.12.001","volume":"329","author":"AK Andrianov","year":"2021","unstructured":"Andrianov, A. K. & Langer, R. Polyphosphazene immunoadjuvants: historical perspective and recent advances. J. Control Release 329, 299\u2013315 (2021).","journal-title":"J. Control Release"},{"key":"1161_CR62","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1021\/acs.molpharmaceut.0c00487","volume":"18","author":"AK Andrianov","year":"2021","unstructured":"Andrianov, A. K. et al. In vivo and in vitro potency of polyphosphazene immunoadjuvants with hepatitis C virus antigen and the role of their supramolecular assembly. Mol. Pharm. 18, 726\u2013734 (2021).","journal-title":"Mol. Pharm."},{"key":"1161_CR63","doi-asserted-by":"publisher","first-page":"E6946","DOI":"10.1073\/pnas.1614942113","volume":"113","author":"BG Pierce","year":"2016","unstructured":"Pierce, B. G. et al. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc. Natl. Acad. Sci. USA 113, E6946\u2013E6954 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR64","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.jmb.2015.06.012","volume":"427","author":"L Kong","year":"2015","unstructured":"Kong, L. et al. Structure of hepatitis C virus envelope glycoprotein E1 antigenic site 314-324 in complex with antibody IGH526. J. Mol. Biol. 427, 2617\u20132628 (2015).","journal-title":"J. Mol. Biol."},{"key":"1161_CR65","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1073\/pnas.1114927109","volume":"109","author":"E Giang","year":"2012","unstructured":"Giang, E. et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. USA 109, 6205\u20136210 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR66","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1128\/JVI.78.13.7257-7263.2004","volume":"78","author":"ZY Keck","year":"2004","unstructured":"Keck, Z. Y. et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78, 7257\u20137263 (2004).","journal-title":"J. Virol."},{"key":"1161_CR67","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1128\/JVI.01138-09","volume":"83","author":"TJ Broering","year":"2009","unstructured":"Broering, T. J. et al. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83, 12473\u201312482 (2009).","journal-title":"J. Virol."},{"key":"1161_CR68","doi-asserted-by":"publisher","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","volume":"79","author":"A Owsianka","year":"2005","unstructured":"Owsianka, A. et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79, 11095\u201311104 (2005).","journal-title":"J. Virol."},{"key":"1161_CR69","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1136\/gutjnl-2020-321190","volume":"70","author":"D Bankwitz","year":"2021","unstructured":"Bankwitz, D. et al. Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. Gut 70, 1734\u20131745 (2021).","journal-title":"Gut"},{"key":"1161_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39659-z","volume":"14","author":"MC Metcalf","year":"2023","unstructured":"Metcalf, M. C. et al. Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies. Nat. Commun. 14, 3980 (2023).","journal-title":"Nat. Commun."},{"key":"1161_CR71","doi-asserted-by":"publisher","first-page":"e0208","DOI":"10.1097\/MD.0000000000010208","volume":"97","author":"Y Guo","year":"2018","unstructured":"Guo, Y. et al. Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. Med. (Baltim.) 97, e0208 (2018).","journal-title":"Med. (Baltim.)"},{"key":"1161_CR72","doi-asserted-by":"publisher","first-page":"e01032","DOI":"10.1128\/JVI.01032-17","volume":"91","author":"BG Pierce","year":"2017","unstructured":"Pierce, B. G. et al. Structure-based design of hepatitis C virus vaccines that elicit neutralizing antibody responses to a conserved epitope. J. Virol. 91, e01032\u201301017 (2017).","journal-title":"J. Virol."},{"key":"1161_CR73","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00216-017-0406-7","volume":"409","author":"A Shajahan","year":"2017","unstructured":"Shajahan, A., Heiss, C., Ishihara, M. & Azadi, P. Glycomic and glycoproteomic analysis of glycoproteins\u2014a tutorial. Anal. Bioanal. Chem. 409, 4483\u20134505 (2017).","journal-title":"Anal. Bioanal. Chem."},{"key":"1161_CR74","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1110\/ps.0207702","volume":"11","author":"J Lebowitz","year":"2002","unstructured":"Lebowitz, J., Lewis, M. S. & Schuck, P. Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci. 11, 2067\u20132079 (2002).","journal-title":"Protein Sci."},{"key":"1161_CR75","unstructured":"Laue, T. M., Shah, B. D., Ridgeway, T. M. & Pelletier, S. L. Analytical Ultracentrifugation in Biochemistry and Polymer Science (Royal Society of Chemistry, 1992)."},{"key":"1161_CR76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92872","volume":"2","author":"JR Bailey","year":"2017","unstructured":"Bailey, J. R. et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight 2, e92872 (2017).","journal-title":"JCI Insight"},{"key":"1161_CR77","doi-asserted-by":"publisher","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","volume":"8","author":"ZY Keck","year":"2012","unstructured":"Keck, Z. Y. et al. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8, e1002653 (2012).","journal-title":"PLoS Pathog."},{"key":"1161_CR78","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","volume":"74","author":"KG Hadlock","year":"2000","unstructured":"Hadlock, K. G. et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74, 10407\u201310416 (2000).","journal-title":"J. Virol."},{"key":"1161_CR79","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1073\/pnas.0711044105","volume":"105","author":"TK Scheel","year":"2008","unstructured":"Scheel, T. K. et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. USA 105, 997\u20131002 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1161_CR80","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/hep.22550","volume":"48","author":"S Marukian","year":"2008","unstructured":"Marukian, S. et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48, 1843\u20131850 (2008).","journal-title":"Hepatology"},{"key":"1161_CR81","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","volume":"133","author":"JM Gottwein","year":"2007","unstructured":"Gottwein, J. M. et al. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a\/2a (S52\/JFH1) viruses. Gastroenterology 133, 1614\u20131626 (2007).","journal-title":"Gastroenterology"},{"key":"1161_CR82","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1086\/593021","volume":"198","author":"TB Jensen","year":"2008","unstructured":"Jensen, T. B. et al. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198, 1756\u20131765 (2008).","journal-title":"J. Infect. Dis."},{"key":"1161_CR83","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent end points. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"1161_CR84","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/biomet\/44.3-4.470","volume":"44","author":"EC Fieller","year":"1957","unstructured":"Fieller, E. C., Hartley, H. O. & Pearson, E. S. Tests for rank correlation coefficients. I. Biometrika 44, 470\u2013481 (1957).","journal-title":"I. Biometrika"},{"key":"1161_CR85","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/biomet\/24.3-4.382","volume":"24","author":"PR Rider","year":"1932","unstructured":"Rider, P. R. On the distribution of the correlation coefficient in small samples. Biometrika 24, 382\u2013403 (1932).","journal-title":"Biometrika"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01161-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:03:05Z","timestamp":1749643385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01161-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1161"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01161-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thomas Fuerst, Nathan Lewis, and Alexander Andrianov are shareholders of NeuImmune, Inc., a company which uses the geCHO platform for the development of vaccines and other biologic therapeutics. This company had no role in the design of the study, collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. These potential conflicts of interest have been disclosed and are managed by the University of Maryland. Eric Toth is one of the holders of the geCHO intellectual property licensed by NeuImmune, Inc. from the University of Maryland. He has disclosed those interests fully to the University of Maryland, and has in place an approved plan for managing any potential conflicts arising from this. The other authors have no conflicts of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}